Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
Cancer Stem Cell News
Cancer Stem Cell News is an online resource that curates the top research publications and reviews about cancer progenitor cells and cancer stem cells.
CDKN1B (P27/Kip1) Enhances Drug-Tolerant Persister CTCs by Restricting Polyploidy Following Mitotic Inhibitors
[Proceedings of the National Academy of Sciences of the United States of America] By studying ex vivo cultures of breast cancer patient-derived circulating tumor cells, investigators identified a CDKN1B-AKT1-dependent mechanism controlling entry into a drug-persistent state.
Hyaluronic Acid-Tailored Prodrug Nanoplatforms for Efficiently Overcoming Colorectal Cancer Chemoresistance and Recurrence by Synergistic Inhibition of Cancer Cell Stemness
[Journal of Nanobiotechnology] Scientists developed a targeted polymer prodrug nanoplatform capable of synergistically inhibiting cancer cell stemness by modulating intracellular metabolism and inhibiting protective autophagy.
Curcumin-Based Polymer Prodrug Nanoplatform for High-Efficiency Immunotherapy by Synergistically Suppression of Head and Neck Cancer Cell Stemness
[Journal of Nanobiotechnology] Researchers introduced a prodrug nanoplatform that overcomes key resistance mechanisms in head and neck cancer by coordinately targeting stemness, inducing dual apoptosis/ferroptosis, and potentiating ICD through PDT/PTT-enhanced immunomodulation.
Novel Mutations of SRPX Facilitate the Stemness and Malignant Progression of Glioma
[British Journal of Cancer] Researchers identified a novel role of SRPX mutations in acceleration to stemness and malignant progression, which could provide new targets in improving outcomes of glioma.
Discovery of Juglone Derivatives As Novel STAT3 Inhibitors with Potent Suppression of Cancer Cell Stemness against Breast Cancer
[Journal of Medicinal Chemistry] A novel STAT3 inhibitor demonstrated potent STAT3 phosphorylation and exhibited nanomolar affinity in binding assays. It exhibited remarkable antiproliferative activity across multiple breast cancer cell lines and selectively suppressed breast CSC self-renewal, outperforming TTI-101 and matching BBI-608 in potency.
The Critical Role of DNA Damage-Inducible Transcript 4 (DDIT4) in Stemness Character of Leukemia Cells and Leukemia Initiation
[Molecular Oncology] Investigators demonstrated the critical role of DDIT4 in the stemness of AE9a leukemia cells and elucidated its underlying mechanism, suggesting that targeting DDIT4 may represent a promising therapeutic strategy for eliminating LSCs in AML1-ETO leukemia.
Induction of Cancer Stem Cells from Mouse Fibroblasts
[Scientific Reports] Investigators suggested that cell-free chromatin particles (cfChPs) circulating in the blood of cancer patients can transform susceptible somatic cells into cancer stem cells, with the potential to promote metastasis.
E2F7 Transcriptionally Upregulates SPC24 to Mediate Aerobic Glycolysis and Facilitate Stemness of Breast Cancer
[Journal of Bioenergetics and Biomembranes] SPC24 reinforced cell stemness through aerobic glycolysis reprogramming, and SPC24 was modulated by transcription factor E2F7. E2F7 transcriptionally activates the upregulation of SPC24 in BC, which boosted stemness through aerobic glycolysis reprogramming.
AZD1080, a Specific Inhibitor of GSK‑3β, Inhibits Stemness and Malignancies in Osteosarcoma Cancer Stem‑like Cells
[Molecular Medicine Reports] Due to the crucial role of glycogen synthase kinase‑3 beta (GSK‑3β) in maintaining stemness, it is considered as an important target for drug development. Scientists evaluated the inhibitory effect of AZD1080, a GSK‑3β inhibitor, on osteosarcoma CSCs.
Navigating Circulating Tumor Cells and Tumor Microemboli: Where We Stand in Bridging their Molecular Dynamics with Clinical Translation
[Biochimica Et Biophysica Acta-Reviews On Cancer] The authors provide a comprehensive and comparative investigation of circulating tumour cells/circulating tumour microemboli biology, highlight recent advancements in their isolation and detection technologies, and underline their growing role along with associated challenges in oncology and clinical management.
Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase I Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+...
[Cue Biopharma, Inc.] Cue Biopharma, Inc. provided a clinical update on its most advanced asset, CUE-101, representative of the CUE-100 series of interleukin 2 (IL-2)-based biologics. It is designed to activate and expand HPV16 tumor-specific T cells by presenting two signals to T cells.
Tailoring a Novel Colorectal Cancer Stem Cell-Targeted Therapy by Inhibiting the SMYD3/C-MYC Axis
[Signal Transduction and Targeted Therapy] Researchers performed an extensive in vitro and in vivo molecular and functional characterization, revealing the pivotal role of the lysine methyltransferase SET and MYND Domain Containing 3 (SMYD3) in colorectal CSC biology.
Cancer Stem Cell News consolidates the most recent publications covering research areas such as the identification and isolation of cancer stem cells, their proliferation and differentiation characteristics, gene expression and regulatory pathways, and the development of anti-cancer therapies. We also include cancer stem cell jobs and events hosted by leading research organizations, societies, and institutes.
